Trinity Biotech Announces Year End Results and a Unigold Contract With the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR)

DUBLIN, IRELAND -- (MARKET WIRE) -- March 06, 2007 -- Trinity Biotech plc (NASDAQ: TRIB) (DUBLIN: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the year ended December 31, 2006 and a new contract for the supply of rapid HIV products to fifteen countries under President Bush’s PEPFAR programme.